117 related articles for article (PubMed ID: 32573588)
1. Ultrasound-responsive alkaline nanorobots for the treatment of lactic acidosis-mediated doxorubicin resistance.
Meng X; Xu Y; Lu Q; Sun L; An X; Zhang J; Chen J; Gao Y; Zhang Y; Ning X
Nanoscale; 2020 Jul; 12(25):13801-13810. PubMed ID: 32573588
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Specific Activatable Nanocarriers with Gas-Generation and Signal Amplification Capabilities for Tumor Theranostics.
Qi C; He J; Fu LH; He T; Blum NT; Yao X; Lin J; Huang P
ACS Nano; 2021 Jan; 15(1):1627-1639. PubMed ID: 33356128
[TBL] [Abstract][Full Text] [Related]
3. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
4. Self-assembled nanoparticles of reduction-sensitive poly (lactic-co-glycolic acid)-conjugated chondroitin sulfate A for doxorubicin delivery: preparation, characterization and evaluation.
Wang XF; Ren J; He HQ; Liang L; Xie X; Li ZX; Zhao JG; Yu JM
Pharm Dev Technol; 2019 Jul; 24(6):794-802. PubMed ID: 30907676
[TBL] [Abstract][Full Text] [Related]
5. TME-Responsive Polyprodrug Micelles for Multistage Delivery of Doxorubicin with Improved Cancer Therapeutic Efficacy in Rodents.
Zhang S; Zhu P; He J; Dong S; Li P; Zhang CY; Ma T
Adv Healthc Mater; 2020 Sep; 9(18):e2000387. PubMed ID: 32815646
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment-Responsive Nanococktails for Synergistic Enhancement of Cancer Treatment via Cascade Reactions.
Chen Q; Ma Y; Bai P; Li Q; Canup BSB; Long D; Ke B; Dai F; Xiao B; Li C
ACS Appl Mater Interfaces; 2021 Feb; 13(4):4861-4873. PubMed ID: 33471499
[TBL] [Abstract][Full Text] [Related]
7. Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death.
Wu H; Ding Z; Hu D; Sun F; Dai C; Xie J; Hu X
J Pathol; 2012 Jun; 227(2):189-99. PubMed ID: 22190257
[TBL] [Abstract][Full Text] [Related]
8. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance.
Ke CJ; Chiang WL; Liao ZX; Chen HL; Lai PS; Sun JS; Sung HW
Biomaterials; 2013 Jan; 34(1):1-10. PubMed ID: 23044041
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Sensitive Biodegradable Nanoparticles of Molecularly Imprinted Polymer-Stabilized Fluorescent Zeolitic Imidazolate Framework-8 for Targeted Imaging and Drug Delivery.
Qin YT; Feng YS; Ma YJ; He XW; Li WY; Zhang YK
ACS Appl Mater Interfaces; 2020 Jun; 12(22):24585-24598. PubMed ID: 32390415
[TBL] [Abstract][Full Text] [Related]
10. Smart responsive-calcium carbonate nanoparticles for dual-model cancer imaging and treatment.
Huang H; Zhang W; Liu Z; Guo H; Zhang P
Ultrasonics; 2020 Dec; 108():106198. PubMed ID: 32590261
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterisation and in vitro and in vivo evaluation of CD44-targeted chondroitin sulphate-conjugated doxorubicin PLGA nanoparticles.
Liu P; Chen N; Yan L; Gao F; Ji D; Zhang S; Zhang L; Li Y; Xiao Y
Carbohydr Polym; 2019 Jun; 213():17-26. PubMed ID: 30879657
[TBL] [Abstract][Full Text] [Related]
12. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
14. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.
Chen WL; Yang SD; Li F; Qu CX; Liu Y; Wang Y; Wang DD; Zhang XN
Acta Biomater; 2018 Nov; 81():219-230. PubMed ID: 30267887
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
16. Lactic Acidosis in Patients with Solid Cancer.
Heneberg P
Antioxid Redox Signal; 2022 Dec; 37(16-18):1130-1152. PubMed ID: 35316087
[No Abstract] [Full Text] [Related]
17. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release.
Ruan S; Cao X; Cun X; Hu G; Zhou Y; Zhang Y; Lu L; He Q; Gao H
Biomaterials; 2015 Aug; 60():100-10. PubMed ID: 25988725
[TBL] [Abstract][Full Text] [Related]
19. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
[TBL] [Abstract][Full Text] [Related]
20. A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance.
Guo L; Xu Y; Zhou A; Zhang L; Sun L; Gao Y; Chen J; Shan X; Zhang J; Ge J; An X; Liu X; Zhang Y; Ning X
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110403. PubMed ID: 31923941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
